Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study. - Huang XY; Shi GM; Zheng ZT; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Hu ZQ; Lu JC; Meng XL; Guo XJ; et al. (BMC medicine, 2025)